Editor's Note: Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run — and has identified the top S&P 500 stock 12 years running. Today, he's giving away his #1 AI stock pick for 2026, free. Click here to get the name and ticker or read more below.

Dear Reader,

I want to give you a free stock pick today.

No strings attached. No credit card required. Just the name, ticker, and my full analysis.

Here's what I can tell you right now:

This company's sales are up 28% year over year. It holds over 30,000 patents in wireless and video technology. And it just earned an A-rating in my proprietary Stock Grader system.

That's the same system that helped me flag Nvidia back in 2005 — before its 82,000% run.

In fact, this system has identified the top-performing S&P 500 stock for 12 years running. Over the years, it has cost me $9 million to build and maintain. And right now, it's flashing its highest possible rating on this AI play.

Click here to see which AI stock my $9 million system is flagging right now, free.

But this pick is just the beginning...

I've also identified three more AI stocks my system shows have the same early-stage characteristics as Nvidia did in 2005.

Click here to get the name and ticker of my #1 AI stock for 2026 in this free briefing, completely free.

Regards,

Louis Navellier

Senior Investment Analyst, InvestorPlace

P.S. My Stock Grader system has cost $9 million to build and maintain. It helped me flag Nvidia at $1 split-adjusted. Today it's flashing its highest rating on one AI stock and I'm giving you the name free. Click here before this briefing comes down.

3 Ways to Invest in the Growing GLP-1 Weight Loss Market

Author: Nathan Reiff. Originally Published: 4/17/2026.

Weight-loss drugs are big business. The GLP-1 receptor agonist market is expected to nearly triple to $185 billion by 2033, a compound annual growth rate of roughly 12.4%. Although this trend is global, the bulk of the market remains in the United States, and U.S. investors can access the growth by targeting companies that manufacture these drugs.

Don’t assume all GLP-1 sales will be dominated by Ozempic or Wegovy, both produced by pharma giant Novo Nordisk A/S (NYSE: NVO). Demand in this emerging space is so strong that many alternatives are appearing quickly, despite a few major players' high profile. Below, we highlight a lesser-known biotech with a promising candidate in development and two exchange-traded funds (ETFs) that offer broader, diversified exposure to the industry.

A Pivot Toward GLP-1 Drugs Could Be Transformational for Structure Therapeutics

Structure Therapeutics (NASDAQ: GPCR) is a biotechnology company focused on therapies targeting G protein-coupled receptors (GPCRs). Historically it worked on treatments for metabolic and inflammatory diseases such as fibrosis and nonalcoholic steatohepatitis.

More recently, Structure has shifted toward GLP-1 drugs. Its candidate aleniglipron has shown about 16.3% weight loss in trials after adjusting for certain factors, and it may offer advantages versus competitors on safety and manufacturing cost.

Though Structure is not yet profitable, it holds a healthy cash position of roughly $1.4 billion, which should provide runway as aleniglipron progresses toward a pivotal Phase 3 trial.

Analysts have noted Structure's potential based on aleniglipron's promise: 15 of 18 analyst ratings are Buy or equivalent. Shares have declined about 20% so far this year amid challenging external conditions, but the consensus price target of $110 implies the stock could more than double from current levels.

The First GLP-1 Agonist ETF Is Building a Track Record of Success

There is substantial potential in the GLP-1 space, as reflected by several ETFs that have launched to capture it. The Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM), which launched in mid-2024, was an early entrant. The actively managed fund takes a relatively focused approach, targeting roughly two dozen pharmaceutical companies positioned to benefit from GLP-1 growth.

Novo Nordisk and major rival Eli Lilly & Co. (NYSE: LLY) together account for nearly 30% of OZEM's portfolio. The fund also includes a mix of domestic and international names to provide geographic diversification.

Importantly, OZEM gives exposure not only to large drugmakers producing GLP-1 therapies but also to companies developing other weight-loss technologies and to firms supporting the supply chain vital for production.

As an active fund, OZEM charges an expense ratio of 0.59%. That is higher than many passive ETFs but competitive among active managers. The fund’s niche focus means it has a modest asset base—about $52 million—and relatively low trading volumes. Still, it has returned an impressive 45% over the past year, rewarding buy-and-hold investors. A modest dividend is an added perk.

Another GLP-1 ETF With a Passive Approach

A passive alternative is the Amplify Weight Loss Drug & Treatment ETF (NYSEARCA: THNR). Like OZEM, THNR charges a 0.59% annual fee and targets roughly two dozen pharmaceutical companies tied to the GLP-1 market. Novo Nordisk and Eli Lilly are significant holdings, but together they make up closer to about a quarter of the portfolio, leaving relatively more room for other names.

The key distinction is that THNR is not actively managed: it tracks an index of companies involved in GLP-1 and related treatments. Its weightings are determined by float-adjusted market capitalization and influenced by factors such as trading volume.

The index is rebalanced quarterly, and some investors may prefer this passive, market-reflective approach over active management.

That said, THNR’s asset base is very small—about $4 million—and trading volume is limited. The fund has returned roughly 30% over the last year, which is solid but below OZEM's performance.

Dear Reader,

In a few short months, the US government could make a sweeping change to bank accounts nationwide.

It will give them unprecedented powers to control your bank account.

They could closely track every transaction... even freeze it.

Fortunately, there are 4 simple steps you can take today that could safeguard your savings.

Discover these 4 simple steps here.

Good luck and God bless!

Martin D. Weiss, PhD Weiss Ratings Founder

ASML Falls Post-Earnings, Chip-Making Expansion Anchors Outlook

Authored by Leo Miller. Publication Date: 4/16/2026.

Semiconductor manufacturing equipment maker ASML Holding (NASDAQ: ASML) took off in 2025 and hasn't looked back. Shares returned nearly 56% last year, and 2026 has seen more of the same — the stock is up more than 35% on the year despite falling 2.4% after ASML's latest earnings report.

Given recent gains, encouraging results and a constructive long-term outlook, ASML remains a focal point for investors. Here's what to know.

ASML Earnings: Solid Beats, Mixed Guidance

In Q1 2026, the Dutch advanced lithography maker reported sales rising 13% year over year (YOY) to €8.77 billion (about $10.35 billion), slightly above analyst estimates of $10.24 billion. The company also beat on the bottom line, posting diluted EPS of €7.15 (about $8.44), up 19% YOY and comfortably above estimates of €7.68 per share.

Guidance for Q2, however, was light. At the midpoint, ASML forecasts revenue of €8.7 billion (about $10.27 billion) versus analyst expectations of €9.08 billion (about $10.72 billion).

Quarterly results can be lumpy for ASML because its machines carry very high price tags. For example, the company's most advanced high-NA extreme ultraviolet (EUV) lithography machine costs around $400 million. Selling or not selling a single unit can swing quarterly revenue materially, so a one-unit shift can bring guidance and expectations into alignment.

That is why annual guidance is a fairer gauge of ASML’s trajectory. The company raised its full-year 2026 midpoint revenue guidance to €38 billion (about $44.84 billion), up from the prior midpoint of €36.5 billion (about $43.07 billion), and slightly above consensus estimates of €37.75 billion (about $44.55 billion).

Still, the full-year beat was modest and Q2 guidance disappointed, and investors often assign outsized importance to near-term numbers. These dynamics likely contributed to the stock’s post-earnings decline, since much of the strong performance had already been priced in. Looking ahead, two key dynamics to watch are ASML's constrained sales capacity and developments in China.

Manufacturing Buildouts Support Strong Multi-Year Demand

ASML’s ability to convert robust demand into immediate sales is constrained by its customers’ limited capacity to take delivery and install equipment. Many customers lack the clean-room space required for these machines, and adding significant clean-room capacity typically requires building new fabrication facilities — a multi-year process.

Notable capex plans underline future demand: Taiwan Semiconductor Manufacturing (NYSE: TSM) expects to spend about $54 billion on capital expenditures in 2026, roughly a 32% increase year over year. Micron Technology (NASDAQ: MU) forecasts an 81% YOY jump in CapEx to $25 billion in 2026 and expects further increases in 2027. Samsung Electronics (OTCMKTS: SSNLF) projects $28 billion, and SK Hynix $24.5 billion. Many of these facility expansions are not expected to come online until 2027 or 2028.

In short, the demand is present, but conversion to sales is time-shifted by construction cycles — a primary reason for ASML’s optimistic long-term outlook.

China Sales Drop, MATCH Act Looms

In Q1, sales to China declined roughly 23% YOY, falling to 19% of total revenue. That pullback reflects a normalization after Chinese customers front-loaded purchases in 2025 ahead of anticipated export controls. But ASML's business in China could weaken further if proposed legislation advances.

The bipartisan Multilateral Alignment of Technology Controls on Hardware (MATCH) Act would, if enacted, ban sales of deep ultraviolet (DUV) lithography machines to China. ASML has not sold EUV machines in China, and DUV accounts for a large portion of its Chinese sales, so a DUV ban would materially reduce ASML's addressable market there. The company states that its 2026 guidance range "accommodates potential outcomes of ongoing discussions around export control."

ASML: Chip Equipment Stalwart Facing High Expectations

ASML remains well positioned given multi-year secular tailwinds, constrained near-term supply conversion and substantial customer capex plans. The China-related regulatory risk is meaningful, but whether the MATCH Act passes is still uncertain. As of mid-April 2026, ASML appears neither substantially undervalued nor overvalued, and analysts at major investment banks have maintained Buy ratings following the earnings release.

Elon’s filing for the SpaceX IPO just hit the mainstream news…

And everyone is wondering how I called it… almost to the exact day being reported.

Well…

I met Elon Musk face to face.

At a private gathering of the world's financial elite, I was one of just two people selected to speak with him personally.

That conversation — combined with three years studying patterns at CIA headquarters — is why my SpaceX prediction was dead on accurate.

And while the mainstream media was playing catch-up...

I had already helped nearly 15,000 Main Street Americans discover the "backdoor" way to stake a claim pre-IPO.

Now the stakes are even higher.

The filing just happened.

21 banks — including JPMorgan, Goldman Sachs, and Morgan Stanley — are preparing to underwrite what they're calling "Project Apex."

The framework for the biggest IPO in Wall Street history.

Everyone is now looking at June.

So here’s what that means for you and your money…

You just got a gift.

A few more weeks to position yourself before the biggest gains are gobbled up by Wall Street insiders.

Once the roadshow kicks off... once the media frenzy begins... once millions of investors scramble to get in...

The window slams shut.

But right now — today — you still have time.

I'm giving away my top pre-IPO SpaceX pick completely free.

No credit card. No email required.

But I wouldn't wait.

June is coming fast.

Click here to get my FREE SpaceX pre-IPO recommendation now.

Yours for peace, prosperity, and liberty, AEIOU,

Dr. Mark Skousen
Macroeconomic Strategist, The Oxford Club

P.S. I've already helped nearly 15,000 everyday investors get positioned before this historic IPO. Now it's your turn. But the window is closing fast.

Get my free recommendation here… before it's too late.

95% Options Surge: Smart Money Bets Big on a Super Micro Bounce

Reported by Jeffrey Neal Johnson. Article Posted: 4/15/2026.

Are you looking for a contrarian artificial intelligence (AI) stock play? The broader technology sector continues to see a boom in infrastructure spending, but Super Micro Computer (NASDAQ: SMCI) has endured a painful, extended correction.

Retail sentiment often turns negative during periods of high volatility. However, a 95% surge in call options volume suggests a very different story: sophisticated traders are aggressively betting that Super Micro has finally hit rock bottom.

Understanding the divergence between falling share prices and bullish options activity can help identify high-reward reversals. Evaluating derivative-market data alongside core business fundamentals explains why Wall Street appears to expect a sharp rebound for the server manufacturer. While retail traders sometimes panic over legal and regulatory headlines, institutional money often uses these dips to secure leveraged positions at a steep discount. A closer look at the data suggests the heavy selling pressure may finally be easing for this popular technology stock.

A Short Squeeze Setup Hard to Ignore

An unusual spike in options volume is a classic contrarian indicator. A call option gives the buyer the right to purchase a stock at a set price before expiration. When call volume jumps 95%, it represents large, leveraged bets on an imminent price rebound.

The options market is currently flashing several bullish signals for the server hardware manufacturer:

• The Put-Call Ratio: The volume put-call ratio sits at a bullish 0.46, meaning bullish call buying is more than double bearish put activity.

• Short Interest Levels: Short interest remains significant at 16.55% of the public float — roughly 83.19 million shares currently sold short.

• Days to Cover: The stock has a 1.4-day cover ratio, indicating how many days it would take short sellers to cover their positions at the current average daily volume.

Heavy call buying combined with elevated short interest creates an environment ripe for a short squeeze. Institutional traders commonly use options to position ahead of a technical reversal. If the stock continues higher, short sellers may be forced to buy back shares to cover losses, and that forced buying can rapidly accelerate the rally — rewarding early contrarian buyers.

$13 Billion Reasons Not to Panic

Recent headlines have weighed on SuperMicro’s stock price, creating the type of contrarian setup option traders seek. The Department of Justice recently opened an export-control probe, which rattled investors. Several law firms have also set a May 26, 2026, deadline for selecting lead plaintiffs in securities class action lawsuits.

Still, the company’s underlying business fundamentals appear strong. SuperMicro recently reported standout results that underscore healthy growth.

• Impressive Revenue Growth: SuperMicro reported Q2 2026 revenue of $12.68 billion, a 123.4% year-over-year increase.

• Earnings Beat: Earnings per share were $0.69, beating the consensus Wall Street estimate of $0.49 by $0.20.

• Confirmed Order Book: SuperMicro maintains a $13 billion confirmed backlog for NVIDIA (NASDAQ: NVDA) Blackwell Ultra platforms.

That sizable backlog helps establish a valuation floor by guaranteeing future cash flow despite short-term regulatory headlines. The global buildout of AI infrastructure makes SuperMicro an important supplier to cloud providers and enterprise data centers.

Management has continued to innovate and gain market share despite the legal overhang. SuperMicro introduced its Gold Series enterprise servers, targeting higher-margin corporate customers, and launched compact, energy-efficient edge systems powered by Advanced Micro Devices (NASDAQ: AMD) EPYC 4005 processors. These product lines indicate operational growth is intact, which likely gives options traders confidence to wager on a technical recovery.

Charting the Rebound and Limiting Your Risk

SuperMicro’s chart suggests a firm bottom may be forming. Shares recently tested a 52-week low of $19.48, which appears to have acted as a hard technical floor. A 16% recovery over five trading days pushed the price back toward $27, breaking above immediate resistance.

Investors can act on this setup using a structured call-spread strategy. Buying the stock outright provides full upside but requires more capital and exposes holders to headline risk. A call spread offers defined risk while allowing participation in an upside move.

In a typical call spread an investor buys a call at a lower strike and sells a call at a higher strike. Selling the higher-strike option offsets part of the premium for the purchased call, limiting both cost and maximum loss. This defined-risk approach is well suited to volatile technology names, letting participants seek gains without taking unlimited downside exposure from outright stock ownership.

Awaiting the May 5 Catalyst

The divergence between bearish headlines and bullish options volume often precedes trend reversals. Cautious investors might add the server maker to their watchlist ahead of the estimated May 5 earnings report.

A confident forward outlook on the upcoming conference call could be the catalyst that clears much of the regulatory noise. Strong guidance would likely validate the options market’s aggressive bullish positioning. Traders who read the derivatives market are already positioning for a rebound, betting that the company’s fundamentals will outlast temporary volatility.